ViCardia Therapeutics, Inc., 2026-05-21
An SEC Form D private-offering notice from San Francisco, CA, a $700,000 filer-stated offering target in Biotech. Filed 2026-05-21. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
ViCardia Therapeutics is a San Francisco clinical stage biopharmaceutical company developing GP531, an infusion therapy targeting mitochondrial dysfunction in heart failure.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Venture Animal Group, Inc., 2026-05-21, $2M, Oakland, CA
- Reprogram Biosciences, Inc., 2026-05-26, $5M, San Carlos, CA
- Be Afraid Media, Inc., 2026-05-21, $1M, Santa Monica, CA
- ONCOSYNERGY, INC., 2026-05-26, $8.2M, Stamford, CT
- VASTAIR INC., 2026-05-21, $200K, San Francisco, CA
- TenNor Therapeutics (Suzhou) Ltd, 2026-05-26, $14.7M, Suzhou
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.